RemeGen Co., Ltd. (SHA:688331)
China · Delayed Price · Currency is CNY 93.66
+3.48 (3.86%)
Oct 27, 2025, 11:29 AM CST
RemeGen Revenue
RemeGen had revenue of 571.98M CNY in the quarter ending June 30, 2025, with 39.06% growth. This brings the company's revenue in the last twelve months to 2.07B, up 47.83% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.07B
Revenue Growth
+47.83%
P/S Ratio
22.95
Revenue / Employee
675.26K
Employees
2,999
Market Cap
47.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.89B |
| Huadong Medicine | 42.62B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |
| Shanghai Fosun Pharmaceutical (Group) | 40.12B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Jiangsu Hengrui Medicine | 30.15B |
| Zhejiang NHU Company | 22.87B |
| Aier Eye Hospital Group | 21.94B |